Quick Answer
Adicet Bio, Inc. reported Net Income of -$116.80 million for fiscal year 2025.
Adicet Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$116.80M +0.3% |
-$117.12M +17.9% |
-$142.66M -104.4% |
-$69.79M -12.6% |
-$62.00M -69.0% |
-$36.68M -30.4% |
| Diluted EPS | -$16.95 +20.5% |
-$21.33 -544.4% |
-$3.31 -94.7% |
-$1.70 +15.0% |
-$2.00 | — |
| Total Assets | $192.35M -12.7% |
$220.22M +6.2% |
$207.29M -37.3% |
$330.69M -2.4% |
$338.94M +120.3% |
$153.84M +88.6% |
| Cash and Equivalents | $38.92M -31.1% |
$56.49M -64.6% |
$159.71M -38.0% |
$257.66M -7.2% |
$277.54M +229.1% |
$84.33M +695.0% |
| Stockholders Equity | $159.21M -14.7% |
$186.61M +9.7% |
$170.18M -41.8% |
$292.34M -3.6% |
$303.13M +176.0% |
$109.83M +281.9% |
| R&D Expense | $99.13M -0.2% |
$99.32M -6.3% |
$106.04M +48.8% |
$71.25M +45.6% |
$48.94M +42.5% |
$34.33M +44.9% |
| Operating Income | -$122.11M +4.3% |
-$127.61M +16.1% |
-$152.04M -109.6% |
-$72.55M -18.1% |
-$61.43M -56.8% |
-$39.19M -24.9% |
| Shares Outstanding | 9.59M +85.8% |
5.16M -88.1% |
43.27M +0.7% |
42.95M +8.1% |
39.74M +101.9% |
19.68M +812.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$26.86M | +11.9% | +14.0% |
| Diluted EPS | September 30, 2025 | -$0.29 | +14.7% | +14.7% |
| Total Assets | September 30, 2025 | $140.48M | -42.9% | -13.8% |
| Cash and Equivalents | September 30, 2025 | $29.10M | -72.4% | -16.2% |
| Stockholders Equity | September 30, 2025 | $109.14M | -48.4% | -18.2% |
| R&D Expense | September 30, 2025 | $22.85M | -13.0% | -19.6% |
| Operating Income | September 30, 2025 | -$27.95M | +15.7% | +13.7% |
| Shares Outstanding | September 30, 2025 | 83.25M | +1.0% | +0.0% |
- Adicet Bio, Inc. reported Net Income of -$116.80 million for fiscal year 2025.
- Adicet Bio, Inc. showed an increase of +0.3% in Net Income compared to the prior fiscal year.
- Adicet Bio, Inc. reported Diluted EPS of $16.95 per share (loss) for fiscal year 2025.
- Adicet Bio, Inc. showed an increase of +20.5% in Diluted EPS compared to the prior fiscal year.
- Adicet Bio, Inc. reported Total Assets of $192.35 million for fiscal year 2025.
- Adicet Bio, Inc. showed a decrease of -12.7% in Total Assets compared to the prior fiscal year.
- Adicet Bio, Inc. reported Cash and Equivalents of $38.92 million for fiscal year 2025.
- Adicet Bio, Inc. showed a decrease of -31.1% in Cash and Equivalents compared to the prior fiscal year.
- Adicet Bio, Inc. reported Stockholders Equity of $159.21 million for fiscal year 2025.
- Adicet Bio, Inc. showed a decrease of -14.7% in Stockholders Equity compared to the prior fiscal year.
- Adicet Bio, Inc. reported R&D Expense of $99.13 million for fiscal year 2025.
- Adicet Bio, Inc. showed a decrease of -0.2% in R&D Expense compared to the prior fiscal year.
- Adicet Bio, Inc. reported Operating Income of -$122.11 million for fiscal year 2025.
- Adicet Bio, Inc. showed an increase of +4.3% in Operating Income compared to the prior fiscal year.
- Adicet Bio, Inc. reported Shares Outstanding of 9.59 million shares for fiscal year 2025.
- Adicet Bio, Inc. showed an increase of +85.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: